Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015436031
Tue, 30.05.2023
CureVac
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
Initiated Phase 1/2 study in seasonal flu with multivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK
Filed infringement counterclaim in U.S. patent litigation with Pfize [ … ]
Tue, 30.05.2023
CureVac
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
Initiated Phase 1/2 study in seasonal flu with multivalent, modified mRNA vaccine candidates; continued execution on infectious disease development program in collaboration with GSK
Filed infringement counterclaim in U.S. patent litigation with Pfize [ … ]
Fri, 19.05.2023
CureVac
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timeline
CureVac is filing counterclaim in U.S. court under nine patents covering foundational mRNA innovations highly [ … ]
Fri, 19.05.2023
CureVac
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
Motion to transfer U.S. litigation to Eastern District of Virginia granted at CureVac's request and expected to significantly accelerate U.S. litigation timeline
CureVac is filing counterclaim in U.S. court under nine patents covering foundational mRNA innovations highly [ … ]
Mon, 08.05.2023
CureVac
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
Initial Phase 1 part started with multivalent modified mRNA influenza vaccine candidates
Candidates developed in collaboration with GSK within broad infectious disease vaccine progr [ … ]
Mon, 08.05.2023
CureVac
CureVac Announces Dosing of First Participant in Combined Phase 1/2 Study of Multivalent, Modified Influenza Vaccine Candidates Developed in Collaboration with GSK
Initial Phase 1 part started with multivalent modified mRNA influenza vaccine candidates
Candidates developed in collaboration with GSK within broad infectious disease vaccine progr [ … ]
Tue, 25.04.2023
CureVac
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
In 2022, ongoing business transformation driven by COVID-19 and flu clinical developments in collaboration with GSK and successful broadening of oncology footprint
Early 2023, strong validation of CureVac’s proprietary mRNA technology pl [ … ]
Tue, 25.04.2023
CureVac
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
In 2022, ongoing business transformation driven by COVID-19 and flu clinical developments in collaboration with GSK and successful broadening of oncology footprint
Early 2023, strong validation of CureVac’s proprietary mRNA technology pl [ … ]
Tue, 18.04.2023
CureVac
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
TÜBINGEN, Germany/ BOSTON, USA – April 18, 2023 – CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financial results, an [ … ]
Tue, 18.04.2023
CureVac
CureVac to Report Fourth Quarter and Full-Year 2022 Financial Results and Business Updates on April 25, 2023
TÜBINGEN, Germany/ BOSTON, USA – April 18, 2023 – CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), will report financial results, an [ … ]